Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IIT2021-16-Hendifar-KetoROCX: A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma

NCT05336266 is registered in ClinicalTrials.gov with Andrew Hendifar, MD as lead sponsor.

NCT NCT05336266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05336266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IIT2021-16-Hendifar-KetoROCX: A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
Lead sponsor
Andrew Hendifar, MD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 1, 2022
Completion date
December 5, 2026
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas cancer, pancreatic cancer, pancreatic ductal adenocarcinoma